All News

Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/iYM3EOdSSM https://t.co/sruLP9adx3

Links:

Dr. John Cush RheumNow ( View Tweet)
child.guttate.psoriasis

Paradoxical Psoriasis in Kids Taking TNF Inhibitors

d Jack Cush, MD

A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor.

Read Article
Slim,waist,obese,obesity

High BMI Increases Arthritis Risk

d Jack Cush, MD

Obesity carries many risks, now a new study in Arthritis & Rheumatology shows that higher body mass index (BMI) increases the risk for several rheumatic diseases, especially in women for both gout and psoriatic arthropathy. 

Read Article
Why Patients Don't Take Medicines This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost. https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi

Links:

Dr. John Cush RheumNow ( View Tweet)
Medicare and Commercial claims analysis shows 1 #RA pts at risk for H Zoster 2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ 3 Higher total costsalso higher in month after HZ https://t.co/iKmvYDqj87 https://t.co/BeZCmMJse7

Links:

Dr. John Cush RheumNow ( View Tweet)
Indian study of 943 AIRD patients (43% RA) starting biologics or JAKi, had TB screening with IGRA assay. 125 pts were IGRA pos. and had LTBI; 124/125 received anti-TB prophylaxis. IGRA Accuracy in predicting absence of TB reactivation = 99.6% https://t.co/KI9vGWpS59 https://t.co/Ne33P51koD

Links:

Dr. John Cush RheumNow ( View Tweet)
Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/hAj3UZjbHJ https://t.co/eQHjEgelRM

Links:

Dr. John Cush RheumNow ( View Tweet)
Cancer Risk From RA, Not the Drugs A large US claims analysis shows RA patients were nearly 2 times more likely (than those without RA) to develop lymphoma or lung cancer and that commonly used RA treatments were also unlikely to increase cancer risk. https://t.co/6yrc0TsT53 https://t.co/WRQzeFoR1Z

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

What is Colchicine Worth? (6.23.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

Read Article
HRT for RA? Not Yet Dr. Aurelie Najm discusses OP0268 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/hoyZ2Ezn4G https://t.co/XWfE1RHwpi

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologic.choice.MD_.jpeg (keep)

Treatment Sequences Define Subphenotypes in RA Patients

d Jack Cush, MD

An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time. 

Read Article
Watch: Should you Assess Rheumatoid Factor Serially? Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy. https://t.co/5e4SiPGDUM https://t.co/CzE597Auwg

Links:

Dr. John Cush RheumNow ( View Tweet)
cost.price_.drugs_.pills_.jpg

Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?

d Jack Cush, MD

Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?

Read Article
Cancer.risk_.jpg

Cancer Risk From RA, Not the Drugs

d Jack Cush, MD

While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy.

Read Article
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd

Links:

Dr. John Cush RheumNow ( View Tweet)
275 early RA pts and after 2 years, 32% reported unacceptable pain (UP). Predictors of UP best seen at 3 mos FUV (not baseline) and included #Tender Jts (not swollen), overall pain, patient global assessment, and HAQ. https://t.co/Zlv3919Ucz https://t.co/1K1zPvhUYi

Links:

Dr. John Cush RheumNow ( View Tweet)
Biosimilars Match Biologic Originators in RA A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA. https://t.co/EO22ThFL5C https://t.co/wlK0e2Cg5l

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/fA6gzta5rx https://t.co/mGdzTqjEr7

Links:

Dr. John Cush RheumNow ( View Tweet)
High Mortality Rates with Depression in Rheumatoid Arthritis A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA). https://t.co/R2MB4bs0Hr https://t.co/rWIfHmBqr8

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

How Often Do You Monitor MTX? (6.16.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. 

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.